Blood test decides lung cancer treatment in new trial
NCT ID NCT07120698
Summary
This study is for people with stage II-IIIB non-small cell lung cancer who have had surgery after initial treatment with immunotherapy and chemotherapy. It tests whether using a sensitive blood test (called MRD) to detect tiny amounts of leftover cancer can help decide who needs more immunotherapy after surgery. The goal is to give extra treatment only to those who need it, aiming to better control the cancer and prevent it from coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong Provincial People's Hospital
RECRUITINGGuangzhou, Guangdong, 510080, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The third people's hospital of chengdu
RECRUITINGChengdu, Sichuan, 610031, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.